Pfizer’s Groton facility plays key role in recent FDA approvals
13 Nov 2018
Pfizer Inc. is on a roll, gaining U.S. Food and Drug Administration approval of three anti-cancer drugs in the last two months.
Lorbrena, the most recently approved of the three, got the nod in early November, Pfizer has announced, following clinical trials that demonstrated its effectiveness in treating non-small cell lung cancer among patients with a specific gene mutation. In October, the FDA approved Talzenna for certain breast cancer patients, and in September it approved Vizimpro, a first-line treatment for patients with metastatic non-small cell lung cancer.
As with virtually all Pfizer products, the drugs were developed, in part, at the New York-based pharmaceutical’s research and development laboratories on Eastern Point Road in Groton.
More Topics
